The Journal of Clinical Investigation http://www.jci.org
Specialized role of migratory dendritic cells
in peripheral tolerance induction
Juliana Idoyaga,1 Christopher Fiorese,1 Lori Zbytnuik,1 Ashira Lubkin,1 Jennifer Miller,2
Bernard Malissen,3 Daniel Mucida,4 Miriam Merad,2 and Ralph M. Steinman1
1Laboratory of Cellular Physiology and Immunology and Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York,
New York, USA. 2The Immunology Institute, Tisch Cancer Institute, and Department of Oncological Sciences, Mount Sinai School of Medicine, New York,
New York, USA. 3Centre d’Immunologie de Marseille-Luminy, INSERM U631, CNRS UMR 6102, Université de la Méditerranée, Marseille, France.
4Laboratory of Mucosal Immunology, The Rockefeller University, New York, New York, USA.
Harnessing DCs for immunotherapies in vivo requires the elucidation of the physiological role of distinct
DC populations. Migratory DCs traffic from peripheral tissues to draining lymph nodes charged with tis-
sue self antigens. We hypothesized that these DC populations have a specialized role in the maintenance of
peripheral tolerance, specifically, to generate suppressive Foxp3+ Tregs. To examine the differential capacity
of migratory DCs versus blood-derived lymphoid-resident DCs for Treg generation in vivo, we targeted a self
antigen, myelin oligodendrocyte glycoprotein, using antibodies against cell surface receptors differentially
expressed in these DC populations. Using this approach together with mouse models that lack specific DC
populations, we found that migratory DCs have a superior ability to generate Tregs in vivo, which in turn dras-
tically improve the outcome of experimental autoimmune encephalomyelitis. These results provide a rationale
for the development of novel therapies targeting migratory DCs for the treatment of autoimmune diseases.
Tregs actively suppress pathogenic self-reactive CD4+ T cells and,
therefore, represent an important avenue for the treatment of
autoimmune diseases (1). The peripheral Treg pool comprises
naturally arising Tregs (nTregs), which originate in the thymus,
and induced Tregs (iTregs), which are generated in the periphery
from naive CD4+ T cells (1, 2). iTreg conversion is triggered by
DCs and requires antigen presentation in the presence of TGF-β
(2, 3). Therefore, in vivo manipulation of DCs for the generation
of antigen-specific iTregs is a potential approach to prevent, halt,
or reverse autoimmune disorders.
The DC lineage is heterogeneous and can be classified on the
basis of phenotype and origin. Lymphoid tissues, i.e., spleen and
tissue-draining LNs, contain lymphoid-resident DCs that arise
from blood-borne precursors (4) and can be loosely categorized
as CD8+ and CD8– DCs, expressing DEC205 (DEC) and DCIR2,
respectively (5, 6). These lymphoid-resident DCs rapidly take up
antigens from the lymph and bloodstream for presentation to
T cells (7). A second group of DCs are migratory DCs, which traf-
fic from peripheral tissues to the draining LN charged with tissue
antigens (8). The nature of migratory DCs depends on the site of
LN drainage. In skin draining LNs (sLNs), migratory DCs include
epidermal Langerhans cells (LCs) and dermal DCs, which consist
of two main subsets, CD103+ and CD11b+ DCs (9, 10).
The general consensus is that DCs control the induction of
adaptive immune responses against pathogens, while maintain-
ing tolerance to self antigens. However, it is becoming more
apparent that not all DCs have the same physiological functions
in vivo. Lymphoid-resident DCs and migratory DCs have distinct
roles in the induction of immune responses under inflammatory
conditions (11–14). Yet the contribution of steady-state DC pop-
ulations to the induction of peripheral tolerance, specifically to
the generation of antigen-specific Foxp3+ Tregs in vivo, has been,
until now, poorly defined. Understanding the functional special-
ization of DC populations is critically important for the ratio-
nal design of novel suppressive therapies and the generation of
DC-targeted vaccines, particularly in the skin, which is the most
attractive site for vaccination (15).
In this study, we used an antigen-targeting approach to address
in vivo the ability of skin migratory versus lymphoid-resident
DCs to promote the development of antigen-specific Tregs.
Taking advantage of the differential expression of 4 surface
receptors, i.e., DEC, Langerin, DCIR2, and triggering receptor
expressed on myeloid cells-like 4 (Treml4), we delivered a self
antigen, myelin oligodendrocyte glycoprotein (MOG), to skin
migratory or lymphoid-resident DCs using anti-receptor–anti-
gen (α-receptor–antigen) fusion mAbs. By applying this strategy
to mice lacking specific DC populations, we found that skin
Langerin+ migratory DCs have a unique ability to promote the
generation of Tregs in vivo. We also show that delivery of a self
antigen to migratory DCs is a promising therapeutic strategy to
induce suppressive, disease-modulating Tregs.
Strategy to target a self antigen to skin migratory or lymphoid-resident
DCs in vivo. We previously reported that Treml4, an Ig superfam-
ily member receptor, is abundantly expressed on splenic CD8+
lymphoid-resident DCs (16, 17), whereas expression of DCIR2 is
restricted to splenic CD8– lymphoid-resident DCs (18, 19). To fur-
ther characterize the expression of these receptors in skin migra-
tory DCs (Figure 1A) and compare it with the expression of DEC
and Langerin, we performed microarray analysis (Figure 1B) and
flow cytometry (Figure 1C) of sLN DC subsets. Skin migratory
DCs lacked Treml4 and Clec4a4 (DCIR2) gene expression, whereas
migratory CD103+ DCs and LCs co-expressed Ly75 (DEC) and
Authorship note: Christopher Fiorese, Lori Zbytnuik, and Ashira Lubkin contrib-
uted equally to this work.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. doi:10.1172/JCI65260.
2 The Journal of Clinical Investigation http://www.jci.org
Cd207 (Langerin) (Figure 1B). Consistent with the gene expres-
sion, α-Treml4 and α-DCIR2 mAbs failed to stain migratory DCs
but labeled CD8+ and CD8– lymphoid-resident DCs, respectively
(Figure 1C). On the other hand, α-DEC mAbs labeled all subsets
of migratory DCs and CD8+ lymphoid-resident DCs (Figure 1C).
α-Langerin mAb labeled migratory CD103+ DCs and LCs (Figure
1A) and poorly labeled CD8+ DCs (Figure 1A, overlaid red dot plot
in population i) as previously reported (20).
Next we asked whether different α-receptor mAbs selectively
targeted distinct DC subset(s) in vivo. Eighteen to 24 hours after
s.c. inoculation, α-DEC and α-Treml4 mAbs were captured by
most CD8+ lymphoid-resident DCs in spleen and sLN, whereas
α-DCIR2 was taken up by a fraction of CD8– DCs (Figure 1D).
α-Langerin mAb was captured by ~50% of CD8+ DCs (Figure 1D),
which corresponds to Langerin expression in this mouse strain
(21). As expected, neither α-Treml4 nor α-DCIR2 mAbs were taken
α-DEC and α-Langerin, but not α-DCIR2 and α-Treml4 mAbs, target skin migratory DCs in vivo. (A) Gating strategy for DC subsets in sLN (see
also Supplemental Figure 1). Live lineage– cells (CD19–Ter119–DX5–CD3ε–) were examined for CD11c and MHC II (center panel). CD11chiMHC IIint
DCs were stained for the expression of CD8 to identify CD8+ (i) and CD8– (ii) DC subsets (left panel). ~25% of CD8+ DCs in B6 mice expressed
Langerin (overlaid red dot plot). CD11cint/hi MHC IIhi migratory DCs were further gated into CD11bhi DCs (iii), CD11b– DCs (iv), Langerin+CD103+
DCs (v), and Langerin+ CD103– LCs (vi). (B) Microarray analysis of Ly75 (DEC), Clec4a4 (DCIR2), Cd207 (Langerin), and Treml4 by distinct
migratory and lymphoid-resident DC subsets sorted from spleen or sLN. Lymphoid-resident DCs were sorted based on CD8 and CD4 expression.
Heat map depicts normalized values averaged from 3 replicates. Red and blue represent high and low relative expression, respectively. (C) Protein
expression of DEC, DCIR2, and Treml4 by distinct DC subsets analyzed by FACS. (D) Langerin-EGFP mice were inoculated s.c. via footpad with
10 μg Alexa Fluor 647–labeled α-receptor mAbs or control Ig mAb (GL117, gray histograms). Uptake of labeled mAb by distinct DC populations
in the spleen and sLN was evaluated 18–24 hours later by FACS. One experiment representative of 2–3 is shown.
The Journal of Clinical Investigation http://www.jci.org
up by migratory DCs, whereas both α-Langerin and α-DEC mAbs
strongly labeled migratory CD103+ DCs and LCs (Figure 1D).
α-DEC was also captured, to some extent, by migratory CD11b+
and CD11b–CD103– DCs in vivo (Figure 1D).
Overall, these data indicate that α-DEC and α-Langerin mAbs tar-
get skin migratory CD103+ DCs and LCs, whereas CD8+ lymphoid-
resident DCs capture α-DEC, α-Treml4, and variable amounts of
α-Langerin mAbs (Table 1). Thus, inoculation of each α-receptor
mAb can be used as a tool to target antigen to specific DC subset(s).
DEC- and Langerin-expressing DCs expand and induce de novo antigen-
specific Foxp3+ T cells. To deliver a self antigen to distinct DC subsets
in vivo, we engineered each α-receptor mAb to express aa 29–59
of MOG (MOGp, Supplemental Figure 2), containing a disease-
causing epitope in EAE, the mouse model for MS (22). MOGp
delivered to DCs using each α-receptor mAb, but not a control
Ig-MOGp mAb without receptor affinity, was efficiently processed
for MHC II presentation, as shown by the proliferation of MOG-
specific CD4+ T cells (Figure 2A).
To compare the ability of distinct DC subsets to generate de novo
Foxp3+ T cells, we evaluated the differentiation of adoptively trans-
ferred naive MOG-specific Foxp3-EGFP– T cells into Foxp3-EGFP+
T cells 7 days after inoculation with α-receptor–MOGp mAbs
(Figure 2B and Supplemental Figure 3A). Strikingly, α-DEC and
α-Langerin mAbs consistently led to greater frequencies and
absolute numbers of MOG-specific Foxp3+ T cells compared with
α-DCIR2 and α-Treml4 mAbs (Figure 2B). Interestingly, α-DEC–
induced Foxp3+ T cells trafficked to both spleen and sLN, while
α-Langerin–induced Foxp3+ T cells remained mostly in the sLN
(Figure 2B), even though α-DEC and α-Langerin mAbs generated
similar amounts of Foxp3+ T cells (total number in spleen plus sLN).
MOG-specific Foxp3+ T cells were not generated with control
Ig-MOGp mAb (Figure 2B), with unconjugated α-Langerin mAb
(Supplemental Figure 4A), or after inoculation of mAbs in DEC-
deficient or Langerin-deficient mice (Supplemental Figure 4B),
indicating that the response was dependent on the delivery of
MOG to DEC+ or Langerin+ DCs. Generation of MOG-specific
Foxp3+ T cells by α-DEC or α-Langerin mAbs was ~100-fold greater
than the same dose of soluble MOG35-55 peptide (MOG35-55p,
Supplemental Figure 4A) and required steady-state DCs, as shown
by the abolition of Foxp3+ T cell generation in the presence of DC-
maturation stimuli (Supplemental Figure 4C) (23).
We further evaluated the ability of distinct DC subsets to
expand transferred nTregs in vivo. Since MOG-specific Foxp3+
nTregs proliferated minimally in response to control Ig–, α-DEC–,
or α-Langerin–MOGp (Supplemental Figure 3B), we co-trans-
ferred MOG-specific naive
T cells as a source for IL-2 (24,
25), along with MOG-specific
Foxp3-EGFP+ nTregs (Figure
2C). As with iTregs, α-DEC and
α-Langerin were more efficient
at stimulating the proliferation
of Foxp3+ nTregs in vivo than
α-DCIR2 and α-Treml4 mAbs
We concluded that DCs
expressing DEC and Langerin
promote de novo induction and
expansion of antigen-specific
Foxp3+ T cells more potently
than Treml4+ or DCIR2+ DCs. Since α-receptor–MOGp mAbs have
a combined action on nTregs and iTregs, for the rest of the study
we opted to transfer total MOG-specific CD4+ T cells.
α-DEC and α-Langerin morepotently generate Foxp3+ T cells than
α-DCIR2 and α-Treml4 mAbs. At all time points tested, MOGp deliv-
ered using α-DEC and α-Langerin mAbs resulted in increased fre-
quencies and total number of MOG-specific Foxp3+ T cells com-
pared with α-DCIR2 and α-Treml4, with a peak between days 7
and 14 (Supplemental Figure 5A). After α-receptor–MOGp mAb
inoculation in steady state, MOG-specific CD4+ T cells lacking
Foxp3 expression peaked on days 4–7, but rapidly declined there-
after (Supplemental Figure 5B), probably by deletion/cell death
(26, 27). As previously described (28), DC targeting in the steady
state did not prime effector CD4+ T cells producing cytokines
(Supplemental Figure 5C).
Given that Foxp3+ T cell conversion in vivo may depend on the
dose of antigen inoculated (23, 29), we tested α-receptor mAbs at
0.3, 3, or 30 μg. Three micrograms was the most effective dose in
generating Foxp3+ T cells, and α-DCIR2 and α-Treml4 were less
efficient than α-Langerin or α-DEC mAbs at all doses tested (Fig-
ure 3A). In addition, α-DCIR2 and α-Treml4 mAbs conjugated
with OVA were ineffective compared with α-DEC and α-Langerin
at driving OVA-specific Treg induction in vivo (data not shown).
Since high numbers of lymphoid-resident DCs express-
ing DCIR2 and Treml4 are localized in the spleen, we injected
α-receptor–MOGp mAbs systemically to facilitate antigen deliv-
ery to these DC subsets. Intraperitoneal and i.v. inoculation of
α-DCIR2 and α-Treml4 mAbs failed to increase the total number
or frequency of MOG-specific Foxp3+ T cells (Figure 3B). Similar
results were obtained upon i.m. administration of α-receptor–
MOGp mAbs (Figure 3B).
We concluded that the reduced ability of α-DCIR2 and α-Treml4
mAbs to generate Foxp3+ T cells was independent of mAb dose,
route of administration, time course, or type of antigen.
Skin Langerin+ migratory DCs control the differentiation of Foxp3+
T cells after inoculation of α-DEC and α-Langerin mAbs. α-DEC and
α-Langerin, but not α-DCIR2 and α-Treml4, mAbs were captured
by migratory DCs expressing Langerin, i.e., CD103+ DCs and LCs
(Table 1); thus, we hypothesized that these subsets generate Foxp3+
T cells more efficiently than lymphoid-resident DCs in vivo.
To rule out a role of CD8+ lymphoid-resident DCs capturing
α-DEC mAbs or α-Langerin mAbs, we used mouse models lacking
specific DC populations. Inoculation of α-Langerin–MOGp mAb
in splenectomized mice yielded similar numbers of MOG-specific
Foxp3+ T cells compared with sham controls (Figure 4A), suggest-
Summary of the uptake of Alexa Fluor 647 mAbs by DC subsets 18–24 hours after s.c. inoculation
Migratory DCs in sLN
CD103+ DCs LCs
AAll values are the percentage of Alexa Fluor 647–positive cells relative to control Ig mAb 18–24 hours after s.c.
inoculation. B20%/70% represents values in sLN and spleen, respectively.
4 The Journal of Clinical Investigation http://www.jci.org
ing that the spleen, which lacks migratory DCs, is dispensable for
this process. Interestingly, injection of α-DEC–MOGp mAb into
splenectomized mice led to increased accumulation of MOG-
specific Foxp3+ T cells in sLN, with total numbers similar to that
induced by α-Langerin (Figure 4A), suggesting that Foxp3+ T cell
induction with α-DEC–MOGp mAb occurs in sLN, but some trans-
genic T cells circulate to the spleen when this organ is present.
We further evaluated the role of skin migratory DCs using Ccr7–/–
mice. CCR7 is required for migratory DCs, but not lymphoid-
resident DCs, to enter the LN in steady state (30). Consequently,
skin migratory DCs are absent in sLN of Ccr7–/– mice, whereas lym-
phoid-resident DCs are still present in substantial numbers in the
sLN and spleen (40%–70% and 90% respectively; Supplemental Fig-
ure 6A). Generation of MOG-specific Foxp3+ T cells was completely
Targeting MOGp to DEC+ and Langerin+ DCs expands and induces de novo Foxp3+ T cells in vivo. (A) Experimental design (left) to assess the
proliferation of MOG-specific CD4+ T cell in sLN 4 days after s.c. inoculation of α-receptor–MOGp mAbs. Histograms (right) are gated on MOG-
specific donor T cells (Vβ11+, CD45.1+), and are representative of 2–3 experiments. (B) De novo induction of Foxp3+ T cells by α-receptor–MOGp
mAbs. 4 × 106 naive CD4+ T cells (CD25–, Foxp3-EGFP–, CD44lo, CD45RBhi) FACS sorted from MOG-specific Foxp3-EGFP reporter mice (see
Supplemental Figure 3A for sorting strategy) were transferred 1 day before the inoculation of 3 μg α-receptor–MOGp mAbs s.c. footpad. Seven
days later, the frequency (left) and total number (right) of induced MOG-specific Foxp3-EGFP+ T cells were analyzed in the sLN or spleen. Bars
are the mean ± SEM of 4–8 mice in 2–4 experiments. (C) Expansion of nTregs by α-receptor–MOGp mAbs. Recipient mice were co-transferred
with 1 × 106 Violet-labeled MOG-specific CD45.1 Foxp3-EGFP+ nTregs and 4 × 106 MOG-specific CD45.2 naive T cells (left panels show sorting
strategy) 1 day before inoculation of 3 μg α-receptor–MOGp mAbs s.c. via footpad. Histograms (right) show the proliferation of Violet-labeled
MOG-specific Foxp3+ nTregs in spleen and sLN and are representative of 2 experiments.
The Journal of Clinical Investigation http://www.jci.org
abolished in Ccr7–/– mice injected with α-DEC– or α-Langerin-
MOGp mAbs or high-dose untargeted MOG35-55p (Figure 4B).
The lack of Foxp3+ T cell generation in Ccr7–/– mice was not due
to lymphoid-tissue structure disruption, as MOG-specific CD4+
T cells proliferated in response to untargeted MOG35-55p (Figure
4C), indicating that other DCs were able to present the antigen but
were unable to induce Foxp3 expression.
Finally, we evaluated the role of skin Langerin+ migratory DCs
in the generation of Foxp3+ T cells. Diphtheria toxin (DT) treat-
ment of Langerin-DTR mice resulted in the complete depletion
of skin Langerin+ migratory DCs (Supplemental Figure 6B) and
abolishment of Foxp3+ T cell generation by α-Langerin–MOGp
mAb, which served as a positive control (Figure 4D). MOG-specific
Foxp3+ T cell generation triggered by α-DEC–MOGp mAb or high-
dose untargeted MOG35-55p was also abrogated in DT-treated
Langerin-DTR mice (Figure 4D).
Together, these results provide strong evidence that skin Lan-
gerin+ migratory DCs, and not CD8+ lymphoid-resident DCs, are
responsible for the in vivo generation of MOG-specific Foxp3+
T cells after DC targeting with α-DEC and α-Langerin, or after
inoculation of a high dose of untargeted peptide.
Both LCs and dermal CD103+ migratory DCs promote Foxp3+ T cell gen-
eration. Given that α-Langerin and α-DEC mAbs target both LCs
and dermal CD103+ migratory DCs (Table 1), we next determined
their specific role in Foxp3+ T cell generation. To limit the delivery
of antigen to each DC subset, we prepared bone marrow chimeras
(31) wherein only radioresistant LCs or radiosensitive dermal DCs
expressed DEC (Figure 5A). Selective targeting of α-DEC–MOGp
mAb to either radioresistant or radiosensitive cells led to efficient
generation of Foxp3+ T cells (Figure 5B). This result indicates that
both subsets of migratory DCs, i.e., LCs and dermal CD103+ DCs,
are able to generate Foxp3+ T cells.
Lung Langerin+ migratory DCs are also able to drive the differentia-
tion of Foxp3+ T cells. The above data suggest that skin Langerin+
migratory DCs potently induce the differentiation of antigen-
specific Foxp3+ T cells in vivo. Migratory DCs coexpressing Lan-
gerin and CD103 are also found in the lung (32, 33). However,
s.c. inoculation of α-Langerin–MOGp mAb failed to accumulate
MOG-specific Foxp3+ T cells in lung draining mediastinal LNs
(Supplemental Figure 7). Thus, to facilitate antigen delivery to
lung DCs, we inoculated α-receptor–MOGp mAbs intranasally.
α-Langerin– and α-DEC–MOGp mAbs administered i.n. potently
induced MOG-specific Foxp3+ T cells at high frequencies and high
absolute numbers, whereas α-DCIR2 did not significantly gener-
ate Foxp3+ T cells compared with control Ig-MOGp (Figure 6, A
and B). Strikingly, and in contrast to s.c. injection, i.n. inoculation
of α-Treml4–MOGp mAb also led to the induction of MOG-spe-
cific Foxp3+ T cells (Figure 6, A and B). In all cases, MOG-specific
T cells were found mainly in mediastinal LN, and very few cells were
recovered from lung, mesenteric LN, spleen, and sLN (Figure 6B).
Antigen delivery with α-DEC and
α-Langerin mAbs is more efficient than
α-DCIR2 and α-Treml4 for the genera-
tion of MOG-specific Foxp3+ T cells. (A)
Dose response of MOG-specific Foxp3+
T cell generation in sLN (left) and spleen
(right). Recipient mice transferred with
4 × 106 MOG-specific CD4+ T cells 1 day
before s.c. inoculation of α-receptor–
MOGp mAbs were analyzed 7 days
later. Mean ± SEM of 3–5 experiments,
with a total of 6–10 mice per group. (B)
As in A, but comparison of different
inoculation routes: s.c. via footpad, i.p.,
i.v., and i.m. Mean ± SEM of 4–8 mice
per group in 2–4 experiments.
6 The Journal of Clinical Investigation http://www.jci.org
Generation of MOG-specific Foxp3+ T cells by α-Treml4–MOGp
mAb prompted us to evaluate the expression of this receptor in
lung DC subsets (Figure 6, C and D). In contrast to the skin, lung
CD103+ migratory DCs also expressed Treml4 transcripts (Fig-
ure 6C) along with Cd207 (Langerin) and Ly75 (DEC), which was
confirmed at the protein level (Figure 6D). Expression of Clec4a4
(DCIR2) was not detected in any subset of lung migratory DCs
(Figure 6, C and D). Together these results show that target-
ing lung CD103+ migratory DCs with α-Langerin–, α-DEC–, or
α-Treml4–MOGp mAbs generates MOG-specific Foxp3+ T cells.
Overall, similar to skin Langerin+ migratory DCs, lung Langer-
in+ migratory DCs are able to promote antigen-specific Foxp3+
T cells in vivo.
Foxp3+ T cells induced by α-DEC– and α-Langerin–MOGp mAbs are
bona fide Tregs capable of preventing EAE. Foxp3+ T cells induced by
α-DEC– and α-Langerin–MOGp mAbs (iTregs) showed consider-
able expression of suppressive molecules such as GITR, CTLA4,
and ICOS but low levels of the IL-7Rα chain (CD127) (Supple-
mental Figure 8A). Induced Foxp3+ T cells also expressed CD5;
however, in contrast to a previous report (34), we did not find
differences in the expression of CD5 between Tregs and CD4+
Foxp3– T cells (Supplemental Figure 8A). Importantly, MOG-
specific Foxp3+ T cells generated in vivo with either α-DEC– or
α-Langerin– MOGp were able to suppress the in vitro prolifera-
tion of MOG-specific CD4+ responder T cells (Supplemental Fig-
ure 8, B–D). Moreover, MOG-specific Foxp3+ T cells were able to
suppress T cells of other specificities only when provided with
their cognate antigen (Supplemental Figure 8, E–F).
We also evaluated the in vivo suppressive function of α-DEC–
and α-Langerin–induced Foxp3+ Tregs. C57BL/6 (B6) mice that
had received transfer of MOG-specific CD4+ T cells and were
immunized with α-receptor–MOGp mAbs were challenged 14
days later for EAE induction (Figure 7A). Pre-treatment of mice
with α-DEC– or α-Langerin conjugated with MOGp, but not
OVA, reduced EAE incidence, delayed onset, and decreased clini-
cal scores compared with control Ig-MOGp–inoculated mice (Fig-
ure 7A, Supplemental Figure 9A and Supplemental Table 1). In
contrast, mice vaccinated with α-DCIR2– and α-Treml4–MOGp
mAbs showed minimal protection, which not significantly differ-
ent from control Ig-MOGp (Figure 7A and Supplemental Table 1),
consistent with their limited ability to generate Foxp3+ T cells.
To further confirm that induced Foxp3+ Tregs were responsi-
ble for EAE prevention, we crossed MOG transgenic mice with
Foxp3-DTR mice (35). We depleted α-Langerin–induced Tregs
expressing Foxp3-DTR using DT (Figure 7B) before EAE induc-
tion. DT treatment led to the abolishment of EAE protection
(Figure 7C), indicating that Foxp3+ Tregs induced by α-Langerin–
MOGp mAbs were responsible for preventing disease onset and
progression in vivo. At the dose used, DT treatment itself did not
contribute to EAE susceptibility (Supplemental Figure 9B). Final-
ly, treatment with α-Langerin– or α-DEC–MOGp mAbs 10 days
after EAE induction, just prior to clinical onset, did not alter the
Skin Langerin+ migratory DCs mediate Foxp3+
T cell generation after α-DEC and α-Langerin
targeting. (A) Generation of MOG-specific
Foxp3+ T cells in sLN of B6 WT, sham, or sple-
nectomized (Splenec) mice. Mice receiving
transfer of 4 × 106 MOG-specific CD4+ T cells
1 day before s.c. inoculation of 3 μg
α-Langerin– or α-DEC–MOGp were analyzed
7 days later. Mean ± SEM of 2 experiments
with 4 mice per group. (B) As in A, but compar-
ing MOG-specific Foxp3+ T cell generation in
sLN and spleen of B6 WT and Ccr7–/– mice.
Mice inoculated with untargeted MOG35-55p
received 300 μg. Mean ± SEM of 4–8 mice in
2–4 experiments. (C) Four-day proliferation of
Violet-labeled MOG-specific CD45.1+CD4+
T cells (4 × 106) transferred into CD45.2 WT or
Ccr7–/– recipient mice 1 day before s.c. inocula-
tion of untargeted MOG35-55p (300 μg). Gates
represent the percentage of donor CD45.1+
T cells undergoing one or more divisions. Plots
are gated on CD3ε+CD4+ T cells and are rep-
resentative of 2 experiments. (D) Generation
of MOG-specific Foxp3+ T cells in sLN of mice
depleted of Langerin+ cells. As in B, but Lan-
gerin-DTR mice were treated with or without
500 ng DT i.v. the day of T cell transfer (day –1),
followed by 250 ng DT i.p. on days 1, 3, and
5. Mean ± SEM of 4–6 mice per group in 2–3
The Journal of Clinical Investigation http://www.jci.org
course of the disease, suggesting that the generation of disease-
protective Tregs by migratory DCs has an optimal therapeutic
window, which probably depends on the inflammatory context
(Supplemental Figure 9C).
Amelioration of EAE in α-Langerin–MOGp–inoculated mice
was associated with reduced infiltration of CD4+ T cells into the
CNS, whereas EAE progression in control Ig-MOGp–treated mice
was associated with high infiltration of CD4+ T cells, including
IFN-γ+ and IL-17A+ T cells (Supplemental Figure 10, A–C). Nota-
bly, these elevated numbers of IFN-γ+ and IL-17A+ T cells were the
result of increased leukocyte infiltration and not due to a change
in their frequency among the CD4+ T cells (Supplemental Figure
10D). Consistent with the limited infiltration of CD4+ T cells, very
few Tregs were detected in the CNS of α-Langerin–MOGp–inocu-
lated mice, while they were present in the control group (Supple-
mental Figure 10C), as previously reported for EAE (36). Together,
these results suggest that EAE protection in our system is probably
occurring in the periphery rather than the CNS.
In summary, our findings demonstrate that α-DEC– and
α-Langerin–MOGp vaccination is a highly effective strategy for
inducing suppressive, disease-modulating Foxp3+ Tregs.
DCs play a pivotal role in regulating the balance between immu-
nity and tolerance. Advances in DC biology and the development
of technologies for manipulating the function of these cells are
revealing their broad therapeutic potential for the treatment of
immune disorders, including autoimmune diseases. However, DCs
are heterogeneous, composed of distinct subsets with specialized
functions. Consequently, the outcome of immune responses is
determined, in part, by the subset of DCs involved. Here we show
that, in the steady state, Langerin+ migratory DCs induce antigen-
specific Foxp3+ Tregs more potently than lymphoid-resident DCs
in vivo. We further demonstrate that targeting a self antigen to
Langerin+ migratory DCs, but not lymphoid-resident DCs, pro-
vides a very effective strategy for modulating autoimmune disease.
Antigen delivery to DCs using α-receptor mAbs is an attractive
strategy for vaccination and therapy, and to date, many receptors
have been harnessed as putative targets (37, 38). We previously
established that priming of Th1 CD4+ and CD8+ T cells is com-
parable whether antigens are delivered to poly(IC)-matured DCs
through DEC, Langerin, Clec9A, or Treml4 (17, 19). In contrast,
delivery of antigen to steady-state DCs using α-DEC mAbs can
lead to tolerance through deletion (26, 27) and/or the generation
of Tregs (23, 39, 40), but it was suggested that CD8+ lymphoid-
resident DCs mediated Treg conversion (41).
Capitalizing on the differential expression of surface recep-
tors by DC subsets, we provide the first evidence that lymphoid-
resident CD8+ and CD8– DCs are inefficient for Treg genera-
tion in vivo, which was corroborated in several ways. First, the
spleen, which lacks migratory DCs and harbors ~10 times more
lymphoid-resident DCs than LN, was dispensable for the genera-
tion of Tregs, suggesting that Foxp3+ T cell conversion occurs in
LN. Second, abolition of Treg induction in Ccr7–/– mice indicates
that migratory DCs are essential for this process. Third, abroga-
tion of Treg induction in DT-treated Langerin-DTR mice, which
conserve ~40%–60% functional CD8+ lymphoid-resident DCs
(42), suggests that Langerin+ migratory DCs are critical for Treg
conversion. Finally, in vivo experiments in bone marrow chimeric
mice demonstrated that LCs and CD103+ migratory DCs potently
and sufficiently generated Tregs to an equivalent degree. Of note,
it has been described that Langerin+CD103+ migratory DCs are
necessary for the generation of pathogenic Th1/Th17 cells after
immunization with MOG35-55p plus CFA (43). Together with our
results, this would suggest that Langerin+CD103+ migratory DCs
could promote either Foxp3+ Tregs in steady state or effector Th1/
Th17 cells under inflammatory conditions.
Importantly, we demonstrated that the Treg-inducing abil-
ity of Langerin+ migratory DCs is not restricted to skin DCs
and is not determined by any particular receptor, as delivery
of MOGp via α-Treml4 mAb to lung Langerin+ migratory DCs
also generated antigen-specific Tregs. Strikingly, Tregs induced
by α-DEC mAb trafficked to the spleen, whereas those induced
by α-Langerin remained mostly in the sLN, suggesting that
α-Langerin mAbs may be effective for treating cutaneous dys-
regulated immune responses.
LCs and dermal CD103+ migratory DCs are able to generate MOG-specific Foxp3+ T cells. (A) Lethally irradiated DEC-deficient mice (Ly75–/–;
CD45.2) and WT (CD45.1) mice were injected with bone marrow cells from WT (CD45.1) or DEC-deficient (Ly75–/–; CD45.2) mice, respectively,
and reconstituted for 12 weeks. The expression of DEC in radiosensitive CD103+ DCs and radioresistant LCs was evaluated by FACS using the
congenic markers CD45.1 and CD45.2 (gating strategy as in Supplemental Figure 1A). Ly75–/– and WT mice were used as controls. (B) Frequency
(left) and total number (right) of Foxp3+ T cells in sLN and spleen from chimeric mice 7 days after s.c. inoculation with 3 μg α-DEC–MOGp mAb,
given 1 day after transfer of 4 × 106 MOG-specific CD4+ T cells. Mean ± SEM of 4–12 mice in 2–4 experiments.
8 The Journal of Clinical Investigation http://www.jci.org
Our results reveal for the first time in vivo that migratory DCs
are superior to lymphoid-resident DCs at inducing antigen-spe-
cific Tregs. Vitali et al. recently reported that migratory DCs are
more efficient than lymphoid-resident DCs at generating Tregs;
however, this comparison was performed in vitro (44). Other in
vivo reports have suggested that dermal Langerin+ DCs present
keratinocyte-associated OVA to OT-II CD4+ T cells, inducing some
Foxp3+ T cells (45). In contrast to the study by Azukizawa et al.,
where only migratory DCs had access to keratinocyte-expressing
antigens, in our targeting system, antigen was accessible to both
migratory DCs and lymphoid-resident DCs, strongly establishing
the superior ability of Langerin+ migratory DCs to induce Tregs
in vivo. Our targeting strategy also revealed the potential of LCs
to induce Tregs in vivo, which is consistent with recent reports
(46, 47). The role of other subsets of migratory DCs, e.g., CD11b+
migratory DCs, in Treg conversion was not assessed and cannot be
excluded. Skin CD11b+ migratory DCs produce retinoic acid (RA)
and have been implicated in Foxp3+ T cell generation in vitro (44,
48). The fact that CD11b+ DCs remain present in DT-treated Lan-
gerin-DTR mice and are able to capture α-DEC mAbs (42) suggests
that migratory CD11b+ DCs are not sufficient to induce antigen-
specific Tregs in vivo. However, RA produced by CD11b+ migratory
DCs might act in a paracrine fashion to increase the numbers of
Tregs induced by Langerin+ migratory DCs.
The properties that distinguish skin Langerin+ migratory DCs
from lymphoid-resident DCs in their capacity to induce Tregs
remain unclear. LCs produce TGF-β, IL-10, and indoleamine
2,3-dioxygenase (IDO) and promote regulatory responses in mice
Lung CD103+ migratory DCs generate MOG-specific Foxp3+ T cells after i.n. inoculation of α-DEC–, α-Langerin–, and α-Treml4–MOGp mAbs.
(A) Foxp3 expression in MOG-specific T cells from mediastinal LN of CD45.2 B6 recipient mice 7 days after i.n. inoculation of 1 μg α-receptor–
MOGp mAbs, given 1 day after transfer of 4 × 106 MOG-specific CD45.1+ T cells. (B) As in A: Percentage of Foxp3+ T cells from CD45.1 trans-
ferred cells (left) or from total CD4+ T cells (right) within lung, mediastinal LN (medLN), mesenteric LN (mesLN), spleen, and sLN. Mean ± SEM
of 3 experiments with 6 mice per group. (C) Microarray analysis of Ly75 (DEC), Clec4a4 (DCIR2), Cd207 (Langerin), and Treml4 by distinct lung
DCs). Heat map depicts normalized values averaged from 3 replicates. Red and blue represent high and low relative expression, respectively.
(D) Histograms show protein levels of DEC, Langerin, DCIR2, and Treml4 in CD103+ and CD11b+ DCs as evaluated by FACS. GL117 control mAb
(gray histograms). One experiment of 2 is shown.
The Journal of Clinical Investigation http://www.jci.org
mus University Medical Center, Rotterdam, Netherlands) (58) were bred in
house as homozygotes to obtain Langerin-deficient mice.
Production of α-receptor–MOGp mAbs. DNA for MOG29-59 (MOGp) was
cloned in frame into the COOH terminus of the heavy chain of α-Langerin
(19), α-DCIR2 (18), and α-Treml4 (17), as previously described for α-DEC,
and a control Ig without receptor affinity (34). mAbs were expressed by
transient transfection (calcium phosphate) in 293T cells in serum-free
DMEM supplemented with Nutridoma SP (Roche), purified on protein
G columns (GE Healthcare), and characterized by SDS-PAGE and Western
blotting using α-mouse IgG1–HRP (Southern Biotech) or biotin-conju-
gated α-MOG (R&D Systems), followed by HRP-Sva (Jackson Immuno-
Research Laboratories Inc.) (Supplemental Figure 2B). mAb binding was
verified on receptor-transfected CHO cells by FACS using PE α-mouse IgG
(Jackson ImmunoResearch Laboratories Inc.) (Supplemental Figure 2C).
Reagents. Fluorochrome-labeled mAbs (see Supplemental Methods).
Other reagents were Cytofix/Cytoperm solution (BD Biosciences), Live/
Dead Fixable Aqua or Blue (Life Technologies), and DAPI (Sigma-Aldrich).
The Foxp3 staining set was from eBiosciences.
Microarray and data analysis. RNA was prepared from purified cell popu-
lations from Langerin-EGFP mice using TRIzol (Life Technologies) as
described previously (59). Populations were sorted (Aria II; BD) using the
ImmGen Standardized Sorting protocol (http://www.ImmGen.org) at the
Mount Sinai Flow Cytometry Shared Resource Facility. RNA was amplified
and hybridized on the Affymetrix Mouse Gene 1.0 ST array according to
the manufacturer’s procedures. All datasets were deposited in the Nation-
al Center for Biotechnology Information/GEO database under accession
number GSE15907. Data generation, pre-processing, normalization, and
quality control were as described previously (59).
Purification of MOG-specific CD4+ T cells. CD4+ T cells were enriched (>90%)
from spleen and LN of 2D2 mice by negative selection using α-F4/80,
and humans (46, 47, 49–51). In the gut, TGF-β and RA have been
shown to control the ability of CD103+ migratory DCs to induce
Tregs in vitro (52). In addition, activation of β-catenin in intestinal
DCs controls the generation of anti-inflammatory mediators and
Tregs (53). Our approach of targeting antigens to functionally spe-
cialized DCs provides a feasible means of studying DC-mediated
mechanisms of tolerance in vivo.
Our work establishes the superior ability of Langerin+ migratory
DCs to induce disease-specific suppressive T cells. Prophylactic
targeting of MOGp to Langerin+ DCs significantly decreased the
incidence and severity of EAE, although the course of the disease
was not altered by targeting migratory DCs 10 days after EAE
induction. Yet it was recently reported that DCs are indispens-
able for induction of Tregs after disease onset (54), suggesting
that our self antigen DC-targeting approach has therapeutic
potential if the right timing for intervention is established.
Further studies will be required in order to pave the way for the
rational design of novel DC-targeting treatments for MS and
other autoimmune disorders.
Mice. B6, Ccr7–/–, and splenectomized and sham-operated mice were
obtained from The Jackson Laboratory. 2D2 mice specific for MOG35-55
(The Jackson Laboratory) (55) were bred in house onto CD45.1, Foxp3-
EGFP reporter mice (The Jackson Laboratory) (56), and Foxp3-DTR mice
(provided by A. Rudensky, Memorial Sloan-Kettering Cancer Center, New
York, New York, USA) (35). Ly75–/– (DEC-deficient) mice were obtained
from M. Nussenzweig (The Rockefeller University) (57) and Langerin-
EGFP/DTR mice from B. Malissen (Université de la Méditerranée, Mar-
seille, France) (21). Langerin-DTR mice (provided by B.E. Clausen, Eras-
α-Langerin– and α-DEC–generated Foxp3+
T cells are functional Tregs that prevent the devel-
opment and progression of EAE. (A) One day
after transfer of 4 × 106 MOG-specific CD4+ T cells
(day –15), B6 mice were inoculated s.c. with 3 μg
α-receptor mAbs (day –14). EAE was induced on
day 0, and disease was monitored for 40 days.
Mean clinical score ± SEM is plotted over time
(10–20 mice in 2–4 experiments). α-DEC and
α-Langerin mAbs were statistically significant
(2-way ANOVA and Bonferroni’s post hoc testing)
from control Ig, α-DCIR2, and α-Treml4 mAbs
(starting on day 17, *P < 0.05). Further information
can be found in Supplemental Table 1. (B) Recipi-
ent B6 mice transferred with 8 × 106 MOG-specific
Foxp3-DTR CD4+ T cells (day –15) 1 day before
s.c. inoculation of 3 μg α-Langerin–MOGp (day
–14) were inoculated i.v. (day –2) and i.p. (day 1)
with 250 ng DT. FACS plots (representative of 3
experiments) show depletion of MOG-specific
Foxp3+ T cells in sLN 1 day after the last DT
inoculation. (C) As in B, but on day 0 mice were
challenged for EAE induction. Data are shown
as the mean clinical score ± SEM of 15–20 mice
per group in 3–4 experiments. The α-Langerin–
MOGp –DT group was statistically significant
(2-way ANOVA and Bonferroni’s post hoc testing)
from the α-Langerin–MOGp +DT and the control
Ig-MOGp groups (starting on day 21, *P < 0.05).
10 The Journal of Clinical Investigation http://www.jci.org
EAE induction. B6 mice were immunized s.c. (into the flanks) with 100 μg
MOG35-55p (synthesized by H. Zebroski, The Rockefeller University) in
complete Freund’s adjuvant (CFA; Difco Laboratories) emulsion contain-
ing 500 μg of Mycobacterium tuberculosis H37 RA (Difco). Animals received
200 ng pertussis toxin i.v. (List Biological Laboratories) on days 0 and 2
after immunization. In some experiments, MOG-specific Foxp3-DTR+ cells
were depleted by inoculation of 250 ng DT administered 2 days before (i.v.)
and 1 day after (i.p.) EAE immunization. Animals were monitored daily
for symptoms and scored in a blinded manner as follows: 0, no disease;
1, limp tail; 2, hind limb weakness; 3, hind limb paralysis; 4, hind limb and
forelimb paralysis; and 5, dead (22). Mice were euthanized and scored 5 if
they reached a score ≥4 for 2 consecutive days.
Statistics. Statistical analysis was performed with Prism software
(GraphPad). Statistical significance between 2 groups was determined
by a 2-tailed Student’s t test. EAE scores were evaluated by 2-way ANOVA
and Bonferroni’s post hoc analysis. P values 0.05 or less were considered
Study approval. All animal studies were approved by the Animal Care and
Use Committee of The Rockefeller University.
The authors thank M. Nulty for help with references, J. Chiappetta
for administrative help, K. Velinzon for cell sorting, S. Yamazaki
for help with Foxp3 staining, and O. Mizenina for technical help.
We thank C. Trumpfheller and A. Gottfried for scientific discus-
sions, writing, and figure formatting; and M. Caskey and I. Matos
for critical reading of the manuscript. This work was supported
by NIAID grant AI13013 (to R.M. Steinman) and NIAMS grant
1K99AR062595 (to J. Idoyaga).
Received for publication June 11, 2012, and accepted in revised
form November 8, 2012.
Address correspondence to: Juliana Idoyaga, 1230 York Avenue,
Box 176, New York, New York 10065, USA. Phone: 212.327.7863;
Fax: 212.327.8875; E-mail: firstname.lastname@example.org.
Ralph M. Steinman is deceased.
α-MHC II (TIB120), α-B220 (RA3-6B2), α-CD8 (2.43), and α-NK1.1
(PK136) mAbs (produced in house), followed by α-rat Dynabeads (Life
Technologies). Naive T cells were FACS purified (Aria II or III; BD) from
2D2 Foxp3-EGFP mice by gating on live CD4+ Foxp3-EGFP–CD25–
CD45RBhiCD44lo. nTregs were FACS purified from 2D2 Foxp3-EGFP
mice by gating on live CD4+ Foxp3-EGFP+. FACS-sorted preparations were
usually of >99% purity. In some cases, 2 × 107/ml CD4+ T cells were labeled
with 5 μM CellTrace Violet (Life Technologies) for 10 minutes at 37°C.
Adoptive transfer of MOG-specific CD4+ T cells. 4 × 106 MOG-specific
CD45.1+CD4+ T cells from 2D2 or 2D2 Foxp3-EGFP mice, or 8 × 106 from
2D2 Foxp3-DTR mice were transferred into B6 CD45.2 recipient mice.
Recipient mice were inoculated 1 day later with different doses (0.3–30 μg)
of α-receptor–MOGp mAbs, control Ig-MOGp, unconjugated α-Langerin
mAbs, or soluble MOG35-55p (3-300 μg). Inoculations were performed s.c.
in footpad (50 μl/hind pad), i.p., i.v., i.m., or i.n. (25 μl/nostril). α-Receptor
mAbs were injected alone or with 25 μg α-CD40 mAb (IC10; produced in
house), 50 μg poly(I:C) (InvivoGen), or 20 μg glucopyranosyl lipid A (GLA;
Immune Design). Langerin-DTR mice were inoculated i.v. with 500 ng DT
(Sigma-Aldrich) on the day of T cell transfer, followed by 250 ng i.p. every
2 days thereafter to maintain DC ablation.
Preparation of cell suspensions. DCs were obtained by digesting spleen or sLN
with 400 U/ml Collagenase D (Roche) and 50 μg/ml DNase I (Roche) for 25
minutes at 37°C. 10 μM EDTA (Life Technologies) was added for the last
5 minutes. DC enrichment was performed with CD11c microbeads (Milt-
enyi Biotec). For analysis of Foxp3 expression, spleen and LNs were force
passed through a 70-μm cell strainer to obtain a homogenous cell suspen-
sion, followed by rbc lysis (BioWhittaker). Lungs of perfused mice were cut
in small pieces and digested with 0.13 U/ml Liberase TM (Roche) and 50
μg/ml DNase I for 30 minutes at 37°C, with 5 μM EDTA added for the
last 5 minutes of incubation. Lung leukocytes were enriched by Percoll (GE
Healthcare) gradient (67.5%–45%) centrifugation (800 g for 15 minutes).
Bone marrow chimeras. 3 × 106 to 5 × 106 bone marrow cells recovered from
tibias and femurs were injected i.v. into lethally irradiated (11.5 Gy in 2
doses, 3 hours apart) recipients. Mice were maintained for 1 month on anti-
biotic-supplemented food (Sulfa-Trim; TestDiet) and water (1.1 mg/ml neo-
mycin; Sigma-Aldrich). Hematopoietic engraftment was analyzed at week 8
using CD45.1/CD45.2 congenic markers (>98% blood B cells, granulocytes,
and monocytes were of donor origin). Mice were used at weeks 12–14.
1. Wing K, Sakaguchi S. Regulatory T cells exert
checks and balances on self tolerance and autoim-
munity. Nat Immunol. 2010;11(1):7–13.
2. Mucida D, Kutchukhidze N, Erazo A, Russo M,
Lafaille JJ, Curotto de Lafaille MA. Oral tolerance
in the absence of naturally occurring Tregs. J Clin
3. Belkaid Y, Oldenhove G. Tuning microenviron-
ments: induction of regulatory T cells by dendritic
cells. Immunity. 2008;29(3):362–371.
4. Liu K, et al. In vivo analysis of dendritic cell
development and homeostasis. Science. 2009;
5. Liu K, Nussenzweig MC. Development and
homeostasis of dendritic cells. Eur J Immunol. 2010;
6. Shortman K, Heath WR. The CD8+ dendritic cell
subset. Immunol Rev. 2010;234(1):18–31.
7. Sixt M, et al. The conduit system transports soluble
antigens from the afferent lymph to resident den-
dritic cells in the T cell area of the lymph node.
8. Randolph GJ, Ochando J, Partida-Sanchez S.
Migration of dendritic cell subsets and their pre-
cursors. Annu Rev Immunol. 2008;26:293–316.
9. Henri S, et al. CD207+ CD103+ dermal dendritic
cells cross-present keratinocyte-derived antigens
irrespective of the presence of Langerhans cells.
J Exp Med. 2010;207(1):189–206.
10. Ginhoux F, et al. Blood-derived dermal langerin+
dendritic cells survey the skin in the steady state.
J Exp Med. 2007;204(13):3133–3146.
11. Villadangos JA, Schnorrer P. Intrinsic and coopera-
tive antigen-presenting functions of dendritic-cell
subsets in vivo. Nat. Rev. Immunol. 2007;7(7):543–555.
12. Heath WR, Carbone FR. Dendritic cell subsets in
primary and secondary T cell responses at body
surfaces. Nat Immunol. 2009;10(12):1237–1244.
13. Lee HK, et al. Differential roles of migratory and
resident DCs in T cell priming after mucosal or skin
HSV-1 infection. J Exp Med. 2009;206(2):359–370.
14. Allenspach EJ, Lemos MP, Porrett PM, Turka LA,
Laufer TM. Migratory and lymphoid-resident den-
dritic cells cooperate to efficiently prime naive CD4
T cells. Immunity. 2008;29(5):795–806.
15. Romani N, Thurnher M, Idoyaga J, Steinman RM,
Flacher V. Targeting of antigens to skin dendritic
cells: possibilities to enhance vaccine efficacy.
Immunol Cell Biol. 2010;88(4):424–430.
16. Hemmi H, et al. A new triggering receptor expressed
on myeloid cells (Trem) family member, Trem-like
4, binds to dead cells and is a DNAX activation
protein 12-linked marker for subsets of mouse
macrophages and dendritic cells. J Immunol. 2009;
17. Hemmi H, et al. Treml4, an Ig superfamily member,
mediates presentation of several antigens to T cells
in vivo, including protective immunity to HER2
protein. J Immunol. 2012;188(3):1147–1155.
18. Dudziak D, et al. Differential antigen process-
ing by dendritic cell subsets in vivo. Science. 2007;
19. Idoyaga J, et al. Comparable T helper 1 (Th1) and
CD8 T-cell immunity by targeting HIV gag p24
to CD8 dendritic cells within antibodies to Lan-
gerin, DEC205, and Clec9A. Proc Natl Acad Sci USA.
20. Cheong C, et al. Production of monoclonal anti-
bodies that recognize the extracellular domain
of mouse Langerin/CD207. J Immunol Methods.
21. Kissenpfennig A, et al. Dynamics and function of
Langerhans cells in vivo: dermal dendritic cells colo-
nize lymph node areas distinct from slower migrat-
ing Langerhans cells. Immunity. 2005;22(5):643–654.
22. Stromnes IM, Goverman JM. Active induction of
experimental allergic encephalomyelitis. Nat Protoc.
23. Kretschmer K, Apostolou I, Hawiger D, Khazaie K,
Nussenzweig MC, von Boehmer H. Inducing and
expanding regulatory T cell populations by foreign
The Journal of Clinical Investigation http://www.jci.org
antigen. Nat Immunol. 2005;6(12):1219–1227.
24. Furtado GC, de Lafaille MA, Kutchukhidze N, Lafaille
JJ. Interleukin 2 signaling is required for CD4+ regula-
tory T cell function. J Exp Med. 2002;196(6):851–857.
25. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY.
A function for interleukin 2 in Foxp3-expressing reg-
ulatory T cells. Nat Immunol. 2005;6(11):1142–1151.
26. Hawiger D, et al. Dendritic cells induce peripheral
T cell unresponsiveness under steady state condi-
tions in vivo. J Exp Med. 2001;194(6):769–780.
27. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nus-
senzweig MC, Steinman RM. Efficient targeting of
protein antigen to the dendritic cell receptor DEC-
205 in the steady state leads to antigen presenta-
tion on major histocompatibility complex class I
products and peripheral CD8+ T cell tolerance.
J Exp Med. 2002;196(12):1627–1638.
28. Bonifaz LC, et al. In vivo targeting of antigens
to maturing dendritic cells via the DEC-205
receptor improves T cell vaccination. J Exp Med.
29. Curotto de Lafaille MA, Lafaille JJ. CD4+ regula-
tory T cells in autoimmunity and allergy. Curr Opin
30. Ohl L, et al. CCR7 governs skin dendritic cell
migration under inflammatory and steady-state
conditions. Immunity. 2004;21(2):279–288.
31. Merad M, et al. Langerhans cells renew in the skin
throughout life under steady-state conditions. Nat
32. Sung SS, Fu SM, Rose CE Jr, Gaskin F, Ju ST, Beaty
SR. A major lung CD103 (αE)-β7 integrin-positive
epithelial dendritic cell population expressing
Langerin and tight junction proteins. J Immunol.
33. Ginhoux F, et al. The origin and development
of nonlymphoid tissue CD103+ DCs. J Exp Med.
34. Hawiger D, Masilamani RF, Bettelli E, Kuchroo VK,
Nussenzweig MC. Immunological unresponsive-
ness characterized by increased expression of CD5
on peripheral T cells induced by dendritic cells in
vivo. Immunity. 2004;20(6):695–705.
35. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T
cells prevent catastrophic autoimmunity through-
out the lifespan of mice. Nat Immunol. 2007;
36. Korn T, et al. Myelin-specific regulatory T cells
accumulate in the CNS but fail to control autoim-
mune inflammation. Nat Med. 2007;13(4):423–431.
37. Steinman RM. Decisions about dendritic cells:
past, present, and future. Annu Rev Immunol. 2012;
38. Trumpfheller C, et al. Dendritic cell-targeted pro-
tein vaccines: a novel approach to induce T-cell
immunity. J Intern Med. 2012;271(2):183–192.
39. Petzold C, Riewaldt J, Koenig T, Schallenberg S,
Kretschmer K. Dendritic cell-targeted pancreatic
beta-cell antigen leads to conversion of self-reactive
CD4(+) T cells into regulatory T cells and promotes
immunotolerance in NOD mice. Rev Diabet Stud.
40. Polansky JK, et al. DNA methylation controls
Foxp3 gene expression. Eur J Immunol. 2008;
41. Yamazaki S, et al. CD8+ CD205+ splenic dendritic
cells are specialized to induce Foxp3+ regulatory T
cells. J Immunol. 2008;181(10):6923–6933.
42. Flacher V, et al. Skin Langerin(+) dendritic cells
transport intradermally injected anti-DEC-205
antibodies but are not essential for subsequent
cytotoxic CD8(+) T cell responses. J Immunol. 2012;
43. King IL, Kroenke MA, Segal BM. GM-CSF-
dependent, CD103+ dermal dendritic cells play a
critical role in Th effector cell differentiation after
subcutaneous immunization. J Exp Med. 2010;
44. Vitali C, et al. Migratory, and not lymphoid-resi-
dent, dendritic cells maintain peripheral self-toler-
ance and prevent autoimmunity via induction of
iTreg cells. Blood. 2012;120(6):1237–1245.
45. Azukizawa H, et al. Steady state migratory RelB+
langerin+ dermal dendritic cells mediate periph-
eral induction of antigen-specific CD4+ CD25+
Foxp3+ regulatory T cells. Eur J Immunol. 2011;
46. Kautz-Neu K, et al. Langerhans cells are negative
regulators of the anti-Leishmania response. J Exp
47. Gomez de Aguero M, et al. Langerhans cells protect
from allergic contact dermatitis in mice by toleriz-
ing CD8+ T cells and activating Foxp3+ regulatory
T cells. J Clin Invest. 2012;122(5):1700–1711.
48. Guilliams M, et al. Skin-draining lymph nodes con-
tain dermis-derived CD103– dendritic cells that con-
stitutively produce retinoic acid and induce Foxp3+
regulatory T cells. Blood. 2010;115(10):1958–1968.
49. Kaplan DH, Li MO, Jenison MC, Shlomchik
WD, Flavell RA, Shlomchik MJ. Autocrine/para-
crine TGFβ1 is required for the development
of epidermal Langerhans cells. J Exp Med. 2007;
50. Seneschal J, Clark RA, Gehad A, Baecher-Allan
CM, Kupper TS. Human epidermal langerhans
cells maintain immune homeostasis in skin by
activating skin resident regulatory T cells. Immun.
51. von Bubnoff D, et al. Human epidermal langer-
hans cells express the immunoregulatory enzyme
indoleamine 2,3-dioxygenase. J Invest Dermatol.
52. Mucida D, et al. Retinoic acid can directly promote
TGF-beta-mediated Foxp3(+) Treg cell conversion
of naive T cells. Immunity. 2009;30(4):471–472;
author reply 472–473.
53. Manicassamy S, et al. Activation of beta-catenin in
dendritic cells regulates immunity versus tolerance
in the intestine. Science. 2010;329(5993):849–853.
54. Yogev N, et al. Dendritic cells ameliorate autoim-
munity in the CNS by controlling the homeosta-
sis of PD-1 receptor+ regulatory T cells. Immunity.
55. Bettelli E, Pagany M, Weiner HL, Linington C,
Sobel RA, Kuchroo VK. Myelin oligodendrocyte
glycoprotein-specific T cell receptor transgenic
mice develop spontaneous autoimmune optic neu-
ritis. J Exp Med. 2003;197(9):1073–1081.
56. Haribhai D, Lin W, Relland LM, Truong N, Wil-
liams CB, Chatila TA. Regulatory T cells dynami-
cally control the primary immune response to for-
eign antigen. J Immunol. 2007;178(5):2961–2972.
57. Guo M, et al. A monoclonal antibody to the DEC-
205 endocytosis receptor on human dendritic cells.
Hum Immunol. 2000;61(8):729–738.
58. Bennett CL, et al. Inducible ablation of mouse Lang-
erhans cells diminishes but fails to abrogate contact
hypersensitivity. J Cell Biol. 2005;169(4):569–576.
59. Miller JC, et al. Deciphering the transcriptional
network of the dendritic cell lineage. Nat Immunol.